Europe Tuberculosis Diagnostics Market Size, Share & Trends Analysis Report By End Use (Diagnostic Laboratories, Hospitals & Clinics, and Others), By Type, By Country and Growth Forecast, 2024 - 2031

The Europe Tuberculosis Diagnostics Market would witness market growth of 4.4% CAGR during the forecast period (2024-2031).

The Germany market dominated the Europe Tuberculosis Diagnostics Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $181.1 million by 2031. The UK market is exhibiting a CAGR of 3.4% during (2024 - 2031). Additionally, The France market would experience a CAGR of 5.3% during (2024 - 2031).

The rise of multidrug-resistant tuberculosis (MDR-TB) represents a significant and growing challenge in the fight against TB. MDR-TB is a form of tuberculosis that is caused by bacteria that are resistant to at least two of the most potent first-line anti-TB drugs, which are rifampicin and isoniazid. This resistance makes MDR-TB much more difficult and costly to treat than drug-susceptible TB, and it has serious implications for public health, as the disease can spread to others, compounding the challenge of TB control. The emergence and spread of MDR-TB have highlighted the critical need for advanced diagnostic tools that can quickly and accurately identify resistant strains, enabling appropriate treatment to be initiated promptly.

The market is not without its challenges. Despite the progress made in developing advanced diagnostic tools, significant barriers remain in terms of accessibility and affordability, particularly in low-income countries where the burden of TB is greatest. Many advanced diagnostic tools are expensive and require infrastructure and expertise, which are often lacking in these settings. This has led to a persistent reliance on older, less effective diagnostic methods, such as smear microscopy, which, while affordable and easy to use, have significant limitations regarding sensitivity and specificity.

TB prevention and awareness programs in France are primarily managed by Santé publique France, the national public health agency. The agency runs national campaigns to raise awareness about TB, particularly in high-incidence areas like Île-de-France. These campaigns often include informational materials distributed in multiple languages to reach immigrant communities and other at-risk groups. The Ministry of Health (Ministero della Salute) coordinates Italy's TB prevention and awareness efforts, focusing on migrant and refugee populations. The country has mandated TB screening for newly arrived asylum seekers as part of a more comprehensive strategy to prevent the transmission of TB within migrant communities. Public health campaigns in Italy are designed to raise awareness about TB symptoms and encourage individuals to seek medical care early. Therefore, as countries across the region continue to implement and refine their TB control strategies, the demand for innovative diagnostics is expected to rise.

Free Valuable Insights: The Global Tuberculosis Diagnostics Market will Hit USD 3.0 Billion by 2031, at a CAGR of 4.7%

Based on End Use, the market is segmented into Diagnostic Laboratories, Hospitals & Clinics, and Others. Based on Type, the market is segmented into Detection of Latent Infection (Skin Test & IGRA), Phage Assay, Detection of Drug Resistance (DST), Nucleic Acid Testing, Radiographic Method, Cytokine Detection Assay, Diagnostic Laboratory Methods, and Other Methods. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

List of Key Companies Profiled

• Abbott Laboratories
• Qiagen N.V
• Thermo Fisher Scientific Inc.
• Becton, Dickinson and Company
• F.Hoffmann-La Roche Ltd.
• Hologic, Inc.
• Danaher Corporation
• DiaSorin S.p.A.
• Bruker Corporation

Europe Tuberculosis Diagnostics Market Report Segmentation

By End Use

• Diagnostic Laboratories
• Hospitals & Clinics
• Others

By Type

• Detection of Latent Infection (Skin Test & IGRA)
• Phage Assay
• Detection of Drug Resistance (DST)
• Nucleic Acid Testing
• Radiographic Method
• Cytokine Detection Assay
• Diagnostic Laboratory Methods
• Other Methods

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Tuberculosis Diagnostics Market, by End Use
1.4.2 Europe Tuberculosis Diagnostics Market, by Type
1.4.3 Europe Tuberculosis Diagnostics Market, by Country
1.5 Methodology for the research

Chapter 2. Market at a Glance
2.1 Key Highlights

Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
3.3 Porter Five Forces Analysis

Chapter 4. Europe Tuberculosis Diagnostics Market by End Use
4.1 Europe Diagnostic Laboratories Market by Country
4.2 Europe Hospitals & Clinics Market by Country
4.3 Europe Others Market by Country

Chapter 5. Europe Tuberculosis Diagnostics Market by Type
5.1 Europe Detection of Latent Infection (Skin Test & IGRA) Market by Country
5.2 Europe Phage Assay Market by Country
5.3 Europe Detection of Drug Resistance (DST) Market by Country
5.4 Europe Nucleic Acid Testing Market by Country
5.5 Europe Radiographic Method Market by Country
5.6 Europe Cytokine Detection Assay Market by Country
5.7 Europe Diagnostic Laboratory Methods Market by Country
5.8 Europe Other Methods Market by Country

Chapter 6. Europe Tuberculosis Diagnostics Market by Country
6.1 Germany Tuberculosis Diagnostics Market
6.1.1 Germany Tuberculosis Diagnostics Market by End Use
6.1.2 Germany Tuberculosis Diagnostics Market by Type
6.2 UK Tuberculosis Diagnostics Market
6.2.1 UK Tuberculosis Diagnostics Market by End Use
6.2.2 UK Tuberculosis Diagnostics Market by Type
6.3 France Tuberculosis Diagnostics Market
6.3.1 France Tuberculosis Diagnostics Market by End Use
6.3.2 France Tuberculosis Diagnostics Market by Type
6.4 Russia Tuberculosis Diagnostics Market
6.4.1 Russia Tuberculosis Diagnostics Market by End Use
6.4.2 Russia Tuberculosis Diagnostics Market by Type
6.5 Spain Tuberculosis Diagnostics Market
6.5.1 Spain Tuberculosis Diagnostics Market by End Use
6.5.2 Spain Tuberculosis Diagnostics Market by Type
6.6 Italy Tuberculosis Diagnostics Market
6.6.1 Italy Tuberculosis Diagnostics Market by End Use
6.6.2 Italy Tuberculosis Diagnostics Market by Type
6.7 Rest of Europe Tuberculosis Diagnostics Market
6.7.1 Rest of Europe Tuberculosis Diagnostics Market by End Use
6.7.2 Rest of Europe Tuberculosis Diagnostics Market by Type

Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 SWOT Analysis
7.2 Qiagen N.V.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Product Launches and Product Expansions:
7.2.6 SWOT Analysis
7.3 Thermo Fisher Scientific, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Product Launches and Product Expansions:
7.3.6 SWOT Analysis
7.4 Becton, Dickinson, and Company
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.4.6 SWOT Analysis
7.5 F. Hoffmann-La Roche Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Acquisition and Mergers:
7.5.6 SWOT Analysis
7.6 Hologic, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 SWOT Analysis
7.7 Danaher Corporation
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 SWOT Analysis
7.8 DiaSorin S.p.A.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expenses
7.8.5 SWOT Analysis
7.9 Bruker Corporation
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expense
7.9.5 SWOT Analysis
7.10. Revvity, Inc.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expenses
7.10.5 SWOT Analysis

TABLE 1 Europe Tuberculosis Diagnostics Market, 2020 - 2023, USD Million
TABLE 2 Europe Tuberculosis Diagnostics Market, 2024 - 2031, USD Million
TABLE 3 Europe Tuberculosis Diagnostics Market by End Use, 2020 - 2023, USD Million
TABLE 4 Europe Tuberculosis Diagnostics Market by End Use, 2024 - 2031, USD Million
TABLE 5 Europe Diagnostic Laboratories Market by Country, 2020 - 2023, USD Million
TABLE 6 Europe Diagnostic Laboratories Market by Country, 2024 - 2031, USD Million
TABLE 7 Europe Hospitals & Clinics Market by Country, 2020 - 2023, USD Million
TABLE 8 Europe Hospitals & Clinics Market by Country, 2024 - 2031, USD Million
TABLE 9 Europe Others Market by Country, 2020 - 2023, USD Million
TABLE 10 Europe Others Market by Country, 2024 - 2031, USD Million
TABLE 11 Europe Tuberculosis Diagnostics Market by Type, 2020 - 2023, USD Million
TABLE 12 Europe Tuberculosis Diagnostics Market by Type, 2024 - 2031, USD Million
TABLE 13 Europe Detection of Latent Infection (Skin Test & IGRA) Market by Country, 2020 - 2023, USD Million
TABLE 14 Europe Detection of Latent Infection (Skin Test & IGRA) Market by Country, 2024 - 2031, USD Million
TABLE 15 Europe Phage Assay Market by Country, 2020 - 2023, USD Million
TABLE 16 Europe Phage Assay Market by Country, 2024 - 2031, USD Million
TABLE 17 Europe Detection of Drug Resistance (DST) Market by Country, 2020 - 2023, USD Million
TABLE 18 Europe Detection of Drug Resistance (DST) Market by Country, 2024 - 2031, USD Million
TABLE 19 Europe Nucleic Acid Testing Market by Country, 2020 - 2023, USD Million
TABLE 20 Europe Nucleic Acid Testing Market by Country, 2024 - 2031, USD Million
TABLE 21 Europe Radiographic Method Market by Country, 2020 - 2023, USD Million
TABLE 22 Europe Radiographic Method Market by Country, 2024 - 2031, USD Million
TABLE 23 Europe Cytokine Detection Assay Market by Country, 2020 - 2023, USD Million
TABLE 24 Europe Cytokine Detection Assay Market by Country, 2024 - 2031, USD Million
TABLE 25 Europe Diagnostic Laboratory Methods Market by Country, 2020 - 2023, USD Million
TABLE 26 Europe Diagnostic Laboratory Methods Market by Country, 2024 - 2031, USD Million
TABLE 27 Europe Other Methods Market by Country, 2020 - 2023, USD Million
TABLE 28 Europe Other Methods Market by Country, 2024 - 2031, USD Million
TABLE 29 Europe Tuberculosis Diagnostics Market by Country, 2020 - 2023, USD Million
TABLE 30 Europe Tuberculosis Diagnostics Market by Country, 2024 - 2031, USD Million
TABLE 31 Germany Tuberculosis Diagnostics Market, 2020 - 2023, USD Million
TABLE 32 Germany Tuberculosis Diagnostics Market, 2024 - 2031, USD Million
TABLE 33 Germany Tuberculosis Diagnostics Market by End Use, 2020 - 2023, USD Million
TABLE 34 Germany Tuberculosis Diagnostics Market by End Use, 2024 - 2031, USD Million
TABLE 35 Germany Tuberculosis Diagnostics Market by Type, 2020 - 2023, USD Million
TABLE 36 Germany Tuberculosis Diagnostics Market by Type, 2024 - 2031, USD Million
TABLE 37 UK Tuberculosis Diagnostics Market, 2020 - 2023, USD Million
TABLE 38 UK Tuberculosis Diagnostics Market, 2024 - 2031, USD Million
TABLE 39 UK Tuberculosis Diagnostics Market by End Use, 2020 - 2023, USD Million
TABLE 40 UK Tuberculosis Diagnostics Market by End Use, 2024 - 2031, USD Million
TABLE 41 UK Tuberculosis Diagnostics Market by Type, 2020 - 2023, USD Million
TABLE 42 UK Tuberculosis Diagnostics Market by Type, 2024 - 2031, USD Million
TABLE 43 France Tuberculosis Diagnostics Market, 2020 - 2023, USD Million
TABLE 44 France Tuberculosis Diagnostics Market, 2024 - 2031, USD Million
TABLE 45 France Tuberculosis Diagnostics Market by End Use, 2020 - 2023, USD Million
TABLE 46 France Tuberculosis Diagnostics Market by End Use, 2024 - 2031, USD Million
TABLE 47 France Tuberculosis Diagnostics Market by Type, 2020 - 2023, USD Million
TABLE 48 France Tuberculosis Diagnostics Market by Type, 2024 - 2031, USD Million
TABLE 49 Russia Tuberculosis Diagnostics Market, 2020 - 2023, USD Million
TABLE 50 Russia Tuberculosis Diagnostics Market, 2024 - 2031, USD Million
TABLE 51 Russia Tuberculosis Diagnostics Market by End Use, 2020 - 2023, USD Million
TABLE 52 Russia Tuberculosis Diagnostics Market by End Use, 2024 - 2031, USD Million
TABLE 53 Russia Tuberculosis Diagnostics Market by Type, 2020 - 2023, USD Million
TABLE 54 Russia Tuberculosis Diagnostics Market by Type, 2024 - 2031, USD Million
TABLE 55 Spain Tuberculosis Diagnostics Market, 2020 - 2023, USD Million
TABLE 56 Spain Tuberculosis Diagnostics Market, 2024 - 2031, USD Million
TABLE 57 Spain Tuberculosis Diagnostics Market by End Use, 2020 - 2023, USD Million
TABLE 58 Spain Tuberculosis Diagnostics Market by End Use, 2024 - 2031, USD Million
TABLE 59 Spain Tuberculosis Diagnostics Market by Type, 2020 - 2023, USD Million
TABLE 60 Spain Tuberculosis Diagnostics Market by Type, 2024 - 2031, USD Million
TABLE 61 Italy Tuberculosis Diagnostics Market, 2020 - 2023, USD Million
TABLE 62 Italy Tuberculosis Diagnostics Market, 2024 - 2031, USD Million
TABLE 63 Italy Tuberculosis Diagnostics Market by End Use, 2020 - 2023, USD Million
TABLE 64 Italy Tuberculosis Diagnostics Market by End Use, 2024 - 2031, USD Million
TABLE 65 Italy Tuberculosis Diagnostics Market by Type, 2020 - 2023, USD Million
TABLE 66 Italy Tuberculosis Diagnostics Market by Type, 2024 - 2031, USD Million
TABLE 67 Rest of Europe Tuberculosis Diagnostics Market, 2020 - 2023, USD Million
TABLE 68 Rest of Europe Tuberculosis Diagnostics Market, 2024 - 2031, USD Million
TABLE 69 Rest of Europe Tuberculosis Diagnostics Market by End Use, 2020 - 2023, USD Million
TABLE 70 Rest of Europe Tuberculosis Diagnostics Market by End Use, 2024 - 2031, USD Million
TABLE 71 Rest of Europe Tuberculosis Diagnostics Market by Type, 2020 - 2023, USD Million
TABLE 72 Rest of Europe Tuberculosis Diagnostics Market by Type, 2024 - 2031, USD Million
TABLE 73 Key Information – Abbott Laboratories
TABLE 74 Key Information – Qiagen N.V.
TABLE 75 Key Information – Thermo Fisher Scientific, Inc.
TABLE 76 Key Information – Becton, Dickinson and Company
TABLE 77 Key Information – F. Hoffmann-La Roche Ltd.
TABLE 78 Key Information – Hologic, Inc.
TABLE 79 Key Information – Danaher Corporation
TABLE 80 Key Information – DiaSorin S.p.A.
TABLE 81 Key Information – Bruker Corporation
TABLE 82 Key Information – Revvity, Inc.

List of Figures
FIG 1 Methodology for the research
FIG 2 Europe Tuberculosis Diagnostics Market, 2020 - 2031, USD Million
FIG 3 Key Factors Impacting Tuberculosis Diagnostics Market
FIG 4 Porter’s Five Forces Analysis – Tuberculosis Diagnostics Market
FIG 5 Europe Tuberculosis Diagnostics Market share by End Use, 2023
FIG 6 Europe Tuberculosis Diagnostics Market share by End Use, 2031
FIG 7 Europe Tuberculosis Diagnostics Market by End Use, 2020 - 2031, USD Million
FIG 8 Europe Tuberculosis Diagnostics Market share by Type, 2023
FIG 9 Europe Tuberculosis Diagnostics Market share by Type, 2031
FIG 10 Europe Tuberculosis Diagnostics Market by Type, 2020 - 2031, USD Million
FIG 11 Europe Tuberculosis Diagnostics Market share by Country, 2023
FIG 12 Europe Tuberculosis Diagnostics Market share by Country, 2031
FIG 13 Europe Tuberculosis Diagnostics Market by Country, 2020 - 2031, USD Million
FIG 14 SWOT Analysis: Abbott Laboratories
FIG 15 Swot Analysis: Qiagen N.V.
FIG 16 SWOT Analysis: Thermo Fisher Scientific, Inc.
FIG 17 SWOT Analysis: Becton, Dickinson and company
FIG 18 SWOT Analysis: F. Hoffmann-La Roche Ltd.
FIG 19 Swot Analysis: Hologic, Inc.
FIG 20 SWOT Analysis: Danaher Corporation
FIG 21 SWOT Analysis: DiaSorin S.p.A.
FIG 22 Swot Analysis: Bruker Corporation
FIG 23 Swot Analysis: Revvity, Inc.